Epigenetics of TNBC in Overweight and Obese Hispanic & Non-Hispanic White Women

University of Arizona

Status: Withdrawn

Conditions: Triple Negative Breast Cancer

Treatments: Procedure: Needle core biopsy

Study type: Observational

Funder types: Other

Identifiers

NCT04291950

32097 (Other Identifier)

2001272738

Details and patient eligibility

About

A key tenet of this project is that of reaching translational human diagnosis and biomarker end points. To lay a foundation and make progress towards these translational goals, investigators will address the following specific aim:

To determine if BMI/ obesity differentially influence expression and epigenetic signatures in triple negative breast cancer (TNBC) from Hispanic compared to NHW women.

Full description

The intended goal of this Project is to develop epigenetic biomarkers to monitor the role of obesity and ethnicity on he development of triple negative breast cancer (TNBC). The proposed approach will seek to clarify for the first time if BMI is a biological factor that regulates aromatic hydrocarbon receptor (AhR) expression and epigenetic activity at breast cancer susceptibility and hormone receptor genes based on Hispanic or non-Hispanic white (NHW) ethnicity. If successful, the proposed experiments have the potential to highlight the role of overweight and obesity for dietary prevention of TNBC and to underscore the consideration of breast cancer screening among overweight/obese Hispanic women. Additionally, this study will provide the opportunity to begin testing the utility of AhR as a biomarker of TNBC development related to BMI and ethnicity.

Sex: Female

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Hispanic or NHW women
• ≥ 18 years of age
• scheduled for a breast procedure as standard of care treatment - benign breast surgery or prophylactic mastectomy\
• Newly diagnosed TNBC - Patients with TNBC will be eligible regardless of whether their treatment plan is surgery first or chemotherapy first (neoadjuvant chemotherapy)
• Eligible non-white women could be included

Exclusion criteria

• BRCA1/2 mutation carriers
• Family history of breast cancer in a first-degree relative and have NOT had genetic testing for BRCA1/2
• Patients who have already undergone radiation or chemotherapy
• Pregnant women
• Male
• Prisoners

Trial design

0 participants in 2 patient groups

Control group

Description:

Hispanic and NHW women undergoing either a benign breast surgery or prophylactic mastectomy.

Treatment:

Procedure: Needle core biopsy

Newly diagnosed TNBC

Description:

Hispanic and NHW with newly diagnosed TNBC. Patients with TNBC will be eligible regardless of whether their treatment plan is surgery first or chemotherapy first (neoadjuvant chemotherapy).

Treatment:

Procedure: Needle core biopsy